U.F.F. De Giorgi - Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 19 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study

C.J. Gratzke, M. Ozguroglu, A. Peer, M.A.N. Sendur, M. Retz, J.C.H. Goh, W.C. Loidl, G. Jayram,S-S. Byun, C. Kwak, M. Kwiatkowski,R. Manneh Kopp,

Annals of Oncology (2023): S957-S958

引用0浏览0引用

771P Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets

U.F.F. De Giorgi, Z. Kuang, N.A. Danziger, J.A. Moore, D.I. Lin,G. Mangili,S. Pignata,E.S. Sokol,S. Sivakumar

Annals of Oncology (2023): S523-S523

引用0浏览0引用

1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status

N. Matsubara, K. Fizazi, A.A. Azad,J. Carles Galceran, A.P. Fay,U.F.F. De Giorgi, J.Y. Joung, P.C. Fong, E. Voog,R.J. Jones, N.D. Shore, C. Dunshee,

Annals of Oncology (2023): S977-S978

引用0浏览0引用

736P Residual masses after salvage chemotherapy in men with metastatic seminoma: The Semi-ResMass multicenter retrospective study

G. Baciarello, C. Brard, H. Baumert,U.F.F. De Giorgi, A. Flechon, P. Giannatempo, G. Gravis, F. Morelli, D. Pouessel,B. Vincenzi, C. Oing, S. Secondino,

Annals of Oncology (2023): S505

引用0浏览0引用

417P New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study

V. Cogliati, E. Rossi, A. Turla, M. Ambroggi, R. Berardi, F. Borella, L. Coltelli,U.F.F. De Giorgi, A. Ferro, O. Garrone, M. Giordano, E. Landucci,

Annals of Oncology (2023): S358-S358

引用0浏览0引用

2088P Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists

A.A. Valsecchi, V. Fusco,M. Di Maio, D. Santini, M. Tucci,U.F.F. De Giorgi, R. Dionisio, F. Vignani, S. Cinieri

Annals of Oncology (2023): S1097-S1098

引用0浏览0引用

1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2

S.M. Yip, K. Fizazi, N. Matsubara, A.A. Azad, J.Y. Joung, P.C. Fong,J. Carles Galceran,U.F.F. De Giorgi,R.J. Jones, G. Liu, A.P. Fay, E. Voog,

Annals of Oncology (2023): S981-S982

引用0浏览0引用

1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)

S.E. Rebuzzi,A. Signori,S. Buti,M. Maruzzo,U.F.F. De Giorgi,P.A. Zucali,G. Procopio,L. Fratino, S. Pipitone,V. Mollica, M. Soraru, S. Chiellino,

Annals of Oncology (2023): S1020-S1020

引用0浏览0引用

400P The impact of CDK4/6 inhibitors on bone health: An Italian real-world experience

R. Scafetta,F. Pantano, M. Donato,C. Fiore, S. Foderaro, A. Guarino, C. Gullotta,L. Sisca, V. Ricozzi,U.F.F. De Giorgi, D. De Lisi,M.A. Fabbri,

Annals of Oncology (2023): S349-S349

引用0浏览0引用

732P Efficacy and safety of high-dose chemotherapy as second or subsequent salvage therapy in relapsed or refractory germ cell cancer patients: A multicentric analysis

C. Seidel,U.F.F. De Giorgi, N. Engel, M. Hentrich, S. Zschäbitz, E. Conolly, A.J. Weickhardt, P. Grimison, V. Wong, C. Oing, W. Alsdorf, C. Schaefers,

Annals of Oncology (2023): S503-S503

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn